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ABSTRACT
Background: The association between pancreatic ductal adenocarcinoma (PDAC) location (head, body,
tail) and tumor stage, treatment and overall survival (OS) is unclear.
Methods: Patients with PDAC diagnosed between 2005 and 2015 were included from the population-
based Netherlands Cancer Registry. Patient, tumor and treatment characteristics were compared with
the tumor locations. Multivariable logistic and Cox regression analyses were used.
Results: Overall, 19,023 patients were included. PDAC locations were 13,451 (71%) head, 2429 (13%)
body and 3143 (16%) tail. Differences were found regarding metastasized disease (head 42%, body
69%, tail 84%, p< .001), size (>4 cm: 21%, 40%, 51%, p< .001) and resection rate (17%, 4%, 7%,
p< .001). For patients without metastases, median OS did not differ between head, body, tail (after
resection: 16.8, 15.0, 17.3 months, without resection: 5.2, 6.1, 4.6 months, respectively). For patients
with metastases, median OS differed slightly (2.6, 2.4, 1.9 months, respectively, adjusted HR body ver-
sus head 1.17 (95%CI 1.10–1.23), tail versus head 1.35 (95%CI 1.29–1.41)).
Conclusions: PDAC locations in body and tail are larger, more often metastasized and less often
resectable than in the pancreatic head. Whereas survival is similar after resection, survival in metasta-
sized disease is somewhat less for PDAC in the pancreatic body and tail.
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Background
Patients with pancreatic ductal adenocarcinoma (PDAC) have
a median overall survival of only 4–6 months [1] and a 5-
year overall survival of 7% [2]. Only 20% of the patients are
amenable to resection. Following resection, the median over-
all survival is 17–21 months and the 5-year overall survival is
16–19% [3–5]. When resection can be combined with adju-
vant chemotherapy, median overall survival increases from 7
months to 26–28 months [6]. Survival with PDAC is
associated with different factors, such as tumor biology,
stage and possible treatment. One of the issues that is still
debated is the association of the primary tumor location
with survival.
Data from the Surveillance, Epidemiology and End Results
(SEER) database showed that patients with PDAC in the pan-
creatic head have higher 3-year relative survival rates than
patients with a PDAC in the pancreatic body or tail in case
of regional (7.6% versus 6.7%) or distant disease (1.8% versus
1.4%). For local disease, results were reversed (9.0% versus
20%) [7]. Another US study investigating the disease-specific
survival by tumor location, reported higher survival rates for
PDAC in the tail than for PDAC in the head for all the stages,
while survival for PDAC in the body was higher than for
PDAC in the head in stage I, but lower in stages II–IV [8]. A
study including patients from a single institution in the US
who underwent resection for PDAC in the period of
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1994–2014, reported similar oncological outcomes between
the tumor locations [5]. However, two of the three studies
did not have recent study periods (1973–2002
and 1985–1995).
Due to the lack of early symptoms due to biliary obstruc-
tion, PDAC in the body or tail are usually more advanced
and are larger at diagnosis than PDAC in the head [5,9]. This
may be the sole explanation for a worse survival in PDAC in
the body or tail. However, a recent clinicopathological study
from Glasgow reported that PDAC of the body and tail may
have a more aggressive tumor biology compared to PDAC of
the head. PDAC of the body and tail was associated with the
PDAC squamous subtype and enriched for gene programmes
associated with inflammation, epithelial-to-mesenchymal
transition and potential immune avoidance mechanisms,
which may also explain worse outcomes in these
patients [10].
The aim of this study is, therefore, to investigate tumor,
patient and treatment characteristics and outcomes of PDAC
in the head, body and tail of all stages in the Netherlands.
Methods
Data collection
This is a retrospective study using data from the nationwide
Netherlands Cancer Registry. The Netherlands Cancer
Registry is a population-based registry which collects data on
all newly diagnosed cancer patients in the Netherlands.
Information on patient and tumor characteristics, diagnosis
and treatment is routinely extracted from the medical
records by trained administrators of the Netherlands Cancer
Registry. Anatomical site of the tumor is registered according
to the International Classification of Disease – Oncology (ICD-
O). The TNM (tumor-node-metastasis) classification is used
for stage notification of the primary tumor, according to the
edition valid at the time of cancer diagnosis. In case of resec-
tion, margin status was classified as microscopically radical
resection (>1mm; R0), microscopically irradical resection
(1mm; R1), and macroscopic irradical resection (R2).
Survival data is obtained by annual linkage with the
Municipal Personal Records Database, which contains infor-
mation on the vital status of all Dutch inhabitants, and is
completed until 1 February 2017.
Study population
For the present study, all the patients with pancreatic ductal
adenocarcinoma (PDAC) or suspected PDAC (ICD-O C25,
morphology codes 8010, 8012, 8020, 8140, 8141, 8260, 8310,
8440, 8480, 8481, 8490, 8500, and 8560, or a non-micro-
scopic verified invasive neoplasm of the pancreas suspected
for adenocarcinoma (i.e., no cytological or histological verifi-
cation) diagnosed between 2005 and 2015 were selected.
Patients younger than 18 years at diagnosis or residing
abroad and patients diagnosed at autopsy were excluded.
Tumor stage was based on pathological TNM stage (for
patients who underwent resection) supplemented by clinical
TNM stage if no pathological TNM stage was available (for
patients without resection; 2005–2009 TNM-6, 2010-2015
TNM-7). Until 2011, a summary stage was recorded for non-
verified cancers. Therefore, tumor stage of all patients was
categorized as: locoregional (tumor confined to the pancreas
or extended to surrounding organs, tissues or regional lymph
nodes), distant metastases (tumor spread to distant lymph
nodes or organs) and unknown. Patients with distant meta-
stases who underwent resection were excluded. Patients
were also classified according to tumor location: head
(C25.0), body (C25.1), tail (C25.2) and other (C25.3–9). The lat-
ter group was excluded. For treatment and survival analysis,
patients who underwent resection, patients without resection
and without distant metastases, and patients with distant
metastases were analyzed separately.
Treatment and outcome measures
Primary outcome of the study was overall survival by tumor
location in relation to resection. For patients undergoing
resection, secondary outcomes included histopathological
margin status, 10 examined lymph nodes, number of posi-
tive lymph nodes, and 30- and 90-day mortality. Type of
resection and the proportions of preoperative and adjuvant
chemotherapy were also investigated. For patients without
resection, the proportion of patients undergoing chemother-
apy was defined.
Statistical analyses
Descriptive statistics were used to compare patient, tumor
and treatment characteristics for all patients and for patients
who underwent resection. Characteristics included gender,
age, tumor stage, microscopic verification and tumor size
(the latter only available in 2015). Included treatments were
resection (mainly pancreatoduodenectomy and distal pan-
createctomy), preoperative, adjuvant and palliative chemo-
therapy. Multivariable logistic regression analyses, presented
as odds ratios with 95% confidence intervals, were used to
determine the independent association of tumor location
with the likelihood of receiving resection (in all patients) and
chemotherapy (in patients who underwent resection,
patients without resection and without distant metastases,
and patients with distant metastases separately). Differences
in 2-year overall survival according to tumor location were
analyzed by means of Kaplan–Meier curves and compared
with Log-Rank tests. Multivariable Cox regression analyses
were used to determine the independent association of
tumor location with long-term survival and the results pre-
sented as hazard ratios with 95% confidence intervals.
Survival time was defined as the time between the date of
diagnosis (for patients without resection) or date of resection
(for patients who underwent resection) and date of death or
censoring (1 February 2017). The variables that were
included in the multivariable analyses (as applicable) were
gender, age (categorized as <65, 65–74 and 75 years),
period of diagnosis (categorized as 2005–2008, 2009–2012
and 2013–2015), tumor stage, resection and preoperative,
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adjuvant and palliative chemotherapy. To investigate
whether the effect of tumor location on survival differed
according to the stage, an interaction term was included in
the model with all patients.
p Values below .05 were considered to be statistically sig-
nificant. SAS/STATVR statistical software (SAS system 9.4, SAS
Institute, Cary, NY) was used for all the analyses.
Results
Study population
The final study population consisted of 19,023 patients with
(suspected) PDAC: 13,451 patients (71%) with PDAC in the
pancreatic head, 2429 patients (13%) in the body and 3143
patients (16%) in the tail (Figure 1).
Table 1 provides an overview of the patient, tumor and
treatment characteristics of the study population by tumor
location. Large differences were especially found for tumor
stage (i.e., proportion metastatic disease in head 42%, body
69%, tail 84%, p< .0001), for tumor size (i.e., proportion
tumor size >4 cm in head 21%, body 40%, tail 51%,
p< .0001) and for microscopic verification (head 63%, body
70%, tail 75%, p< .0001).
For all the patients groups, chemotherapy rates were low
(Table 2). Patients who received chemotherapy were younger
than patients who did not receive chemotherapy, yet gender,
tumor location and tumor size were similar in the three
groups. Clinical characteristics of the patients with and with-
out chemotherapy are provided in Supplementary Table S1.
Overall, patients who received palliative chemotherapy had
significantly better survival compared to patients without
chemotherapy (median overall survival in patients without
resection, no metastases with or without chemotherapy: 10.4
versus 4.3 months, and similarly, in patients without resec-
tion, but with metastases: 5.8 versus 1.6 months, respectively,
both p< .0001, Supplementary Figure S1). Patients with a
PDAC in the head more often underwent resection than
patients with a PDAC in the body or tail (17% versus 4% ver-
sus 7%, respectively, p< .0001). After adjustment for gender,
age, period of diagnosis, and tumor stage, patients with a
PDAC in the body were still less likely to undergo a resec-
tion, as compared to the patients with a PDAC in the head
(adjusted odds ratio (OR) 0.29, 95% CI 0.24–0.37), while
patients with a PDAC in the tail were more likely to undergo
a resection (adjusted OR tail versus head 1.46, 95% CI 1.19–1.
78) (Table 2).
For all stages combined, median overall survival was 4.5
months for PDAC in the head, 3.3 months for body and 2.2
months for tail (Figure 2(A)). The interaction test between
tumor location and stage was significant (p< .0001), indicat-
ing that the association between tumor location and overall
survival differed according to stage. For tail versus head, sur-
vival was better in locoregional disease (HR 0.84, 95% CI
0.76–0.93) but worse in metastatic disease (HR 1.20, 95% CI
1.15–1.26). For body versus head, survival was worse in
locoregional disease (HR 1.15, 95% CI 1.06–1.24) but similar
in metastatic disease (HR 1.02, 95% CI 0.97–1.08).
Table 1. Patient, tumor and treatment characteristics by PDAC location in the
pancreas (n¼ 19,023).
Head Body Tail
p-valuen (%) n (%) n (%)
Total n 13451 2429 3143
Gender
Male 6672 (50) 1158 (48) 1724 (55) <.0001
Female 6779 (50) 1271 (52) 1419 (45)
Age
<65 years 3909 (29) 795 (33) 1060 (34) <.0001
65–74 years 4231 (31) 831 (34) 1148 (36)
75 years 5311 (40) 803 (33) 935 (30)
Tumor stage
Locoregional 7154 (53) 713 (29) 466 (15) <.0001
Distant metastases 5644 (42) 1671 (69) 2637 (84)
Unknown 653 (5) 45 (2) 40 (1)
Microscopically verified
Yes 8478 (63) 1706 (70) 2368 (75) <.0001
No 4973 (37) 723 (30) 775 (25)
Tumor size (2015 only)
0–2 cm 155 (13) 28 (10) 11 (3) <.0001
>2–4 cm 618 (51) 98 (34) 97 (27)
>4 cm 249 (21) 118 (40) 182 (51)
Unknown 188 (15) 48 (16) 67 (19)
Resection
Yes 2320 (17) 107 (4) 207 (7) <.0001
No 11131 (83) 2322 (96) 2936 (93)
Figure 1. Selection of the study population.
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Patients who underwent resection
Some 2621 patients underwent resection, additional charac-
teristics of these patients per tumor location are presented
in Table 3. In patients with a PDAC in the body, 32% under-
went a pancreatoduodenectomy and 61% a distal pancrea-
tectomy. Margin status did not differ significantly between
the tumor locations (p¼ .066), as well as 30 or 90 day
postoperative mortality (p¼ .501 and p¼ .256 respectively).
Approximately half of the patients received chemotherapy,
regardless of tumor location (Table 2). Preoperative chemo-
therapy was mainly administered to patients with a PDAC in
the body, while adjuvant chemotherapy was less often admin-
istered to the patients with a PDAC in the body (Table 3). In
the group of patients who underwent resection, median over-
all survival was 16.8, 15.0 and 17.3 months, respectively for
Table 2. Logistic regression analyses predicting the provision of treatment.
Tumor location Treated (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
All patients (n¼ 19023)
Treatment: resection Head 17 1.00 (reference) 1.00 (reference)a
Body 4 0.22 (0.18–0.27) 0.29 (0.24–0.37)a
Tail 7 0.34 (0.29–0.39) 1.46 (1.19–1.78)a
Patients who underwent resection (n¼ 2621)
Treatment: chemotherapy Head 48 1.00 (reference) 1.00 (reference)b
Body 51 1.13 (0.77–1.68) 0.87 (0.57–1.12)b
Tail 48 1.00 (0.74–1.32) 0.81 (0.59–1.12)b
Patients without resection and without distant metastases (n¼ 5712)
Treatment: chemotherapy Head 15 1.00 (reference) 1.00 (reference)b
Body 30 2.47 (2.04–2.99) 2.03 (1.64–2.51)b
Tail 20 1.42 (1.03–1.94) 1.24 (0.88–1.74)b
Patients with distant metastases (n¼ 9952)
Treatment: chemotherapy Head 22 1.00 (reference) 1.00 (reference)b
Body 30 1.51 (1.33–1.70) 1.46 (1.28–1.66)b
Tail 28 1.34 (1.21–1.49) 1.24 (1.11–1.39)b
Note: Bold text indicates statistically significant findings.
aOdds ratio adjusted for gender, age, period of diagnosis and tumor stage.
bOdds ratio adjusted for gender, age, and period of diagnosis.
Figure 2. Overall survival by tumor location. Starting point survival analyses: A-C-D: date of diagnosis; B: date of resection.
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tumor location head, body and tail (Figure 2(B)). Two-year
overall survival for head, body and tail were 36.2%, 36.9% and
37.9% respectively, while 5-year overall survival was 14.1%,
6.9% and 20.4% respectively. Also in multivariable analysis
adjusting for patient, tumor and treatment characteristics, sur-
vival was similar for all tumor locations (Table 4).
Patients without resection and without metastases
The study population comprised 5712 patients without resec-
tion and without metastases. Of these patients, the
proportion treated with chemotherapy was 15%, 30% and
20% for the patients with a PDAC in the head, body or tail,
respectively. In unadjusted analyses, the odds of receiving
chemotherapy were higher for both tumor locations body
and tail compared to tumor location head. However, after
adjustment for patient and tumor characteristics, only
patients with a PDAC in the body were more likely to receive
chemotherapy compared to patients with a PDAC in the
head (adjusted OR 2.03, 95% CI 1.64–2.51) (Table 2). Median
overall survival in this subgroup was 5.2 months for head,
6.1 months for body and 4.6 months for tail (Figure 2(C)). In
unadjusted analysis, survival was better for patients with a
PDAC in the body than for patients with a PDAC in the
head. However, in multivariable analysis, survival was similar
(Table 4).
Patients with distant metastases
There were 9,952 patients with distant metastases included
in the study. The proportions of patients treated with
chemotherapy by tumor location were: 22% for head, 30%
for body and 28% for tail. Both in univariable and multivari-
able analyses, the odds of receiving chemotherapy was
higher for patients with a PDAC in the body (adjusted OR
1.46, 95% CI 1.28–1.66) and for patients with a PDAC in the
tail (adjusted OR 1.24, 95% CI 1.11–1.39) compared to
patients with a PDAC in the head (Table 2).
Median overall survival was 2.6 months for PDAC in the
head, 2.4 months for PDAC in the body and 1.9 months for
PDAC in the tail (Figure 2(D)). Survival was worse for patients
with a PDAC in the body and tail compared to patients with
a PDAC in the head (body: adjusted HR 1.17, 95% CI
1.10–1.23; and tail: adjusted HR 1.35, 95% CI 1.29–1.41)
(Table 4).
Discussion
This first population-based analysis focusing on the associ-
ation between PDAC location and tumor stage, treatment,
and survival found that PDAC locations in the pancreatic
body or tail are larger, more often metastasized and less
Table 4. Cox regression analyses.
Tumor
location
Median
OS (months)
1-year
OS (%)
2-year
OS (%)
5-year
OS (%)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Adjusted HR
(95% CI)
without treatment with treatment
Patients who underwent
resection (n¼ 2621)
Head 16.8 68.10% 36.20% 14.10% 1.00 (reference) 1.00 (reference)B 1.00 (reference)Bþ
Body 15 65.40% 36.90% 6.90% 1.15 (0.93–1.43) 1.24 (0.99–1.54)B 1.23 (0.99–1.53)Bþ
Tail 17.3 63.60% 37.90% 20.40% 0.89 (0.76-1.05) 0.95 (0.81-1.12)B 0.94 (0.79–1.11)Bþ
Patients without resection
and without distant
metastases (n¼ 5712)
Head 5.2 21.40% 4.90% 1.00% 1.00 (reference) 1.00 (reference)C 1.00 (reference)Cþ
Body 6.1 26.30% 6.70% 1.40% 0.87 (0.80–0.95) 0.90 (0.82–0.98)C 0.96 (0.88–1.05)Cþ
Tail 4.6 18.50% 8.20% 2.50% 1.01 (0.89-1.14) 1.02 (0.90-1.16)C 1.03 (0.91–1.17)Cþ
Patients with distant meta-
stases (n¼ 9952)
Head 2.6 1.00 (reference) 1.00 (reference)D 1.00 (reference)Dþ
Body 2.4 1.03 (0.97–1.08) 1.07 (1.01–1.13)D 1.17 (1.10–1.23)Dþ
Tail 1.9 1.20 (1.15–1.26) 1.16 (1.11–1.22)D 1.35 (1.29–1.41)Dþ
Note: Bold text indicates statistically significant findings.
BOdds ratio adjusted for gender, age, period of diagnosis and tumor stage;þ (neo)adjuvant chemotherapy.
COdds ratio adjusted for gender, age, period of diagnosis and tumor stage;þ palliative chemotherapy.
DOdds ratio adjusted for gender, age and period of diagnosis;þ palliative chemotherapy.
Table 3. Characteristics of patients undergoing resection of PDAC according
to tumor location (n¼ 2,621; 2005–2015).
Head Body Tail p-value
Pathological tumor stage
T1-3 Nany 2176 (94) 98 (94) 194 (94) .858
T4 Nany 103 (5) 5 (5) 11 (5)
TX Nany 32 (1) 1 (1) 1 (1)
Type of resection
Pancreatoduodenectomy 2283 (99) 33 (32) 8 (4) <.0001
Distal pancreatectomy 0 (0) 64 (61) 196 (95)
Other/unknown 28 (1) 7 (7) 2 (1)
Margin status
R0 1428 (62) 60 (58) 131 (63) .066
R1–2 712 (31) 32 (31) 51 (25)
Unknown 171 (7) 12 (11) 24 (12)
10 examined lymph nodes
Yes 1320 (57) 57 (55) 95 (46) .016
No 922 (40) 46 (44) 106 (52)
Unknown 69 (3) 1 (1) 5 (2)
Number of positive lymph nodes
0 680 (29) 43 (41) 91 (44) <.0001
1-3 966 (42) 38 (37) 85 (41)
4 609 (26) 16 (15) 20 (10)
Unknown 56 (3) 7 (7) 10 (5)
Death 30-day postoperatively
Yes 83 (4) 6 (6) 7 (3) .501
No 2228 (96) 98 (94) 199 (97)
Death 90-day postoperatively
Yes 154 (7) 11 (11) 12 (6) .256
No 2157 (93) 93 (89) 194 (94)
Preoperative chemotherapya
Yes 67 (3) 11 (11) 5 (2) <.0001
No 2244 (97) 93 (89) 201 (98)
Adjuvant chemotherapy
Yes 1038 (45) 42 (40) 93 (45) .657
No 1273 (55) 62 (60) 113 (55)
aNeoadjuvant or induction chemotherapy before tumor resection.
*p-value indicates significance of the Chi-square test or Fisher’s Exact test as
appropriate.
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often resectable than PDAC in the pancreatic head. Only in
the patients with metastasized disease, overall survival of
patients with a PDAC in the body or tail was significantly
worse than of patients with a PDAC in the head.
This is the first study in which tumor, treatment and sur-
vival of PDAC in head, body and tail are investigated separ-
ately. Our findings are in line with previous studies [5,7,8,11].
One study describes similar resection rates for body and tail
PDAC compared to head PDAC [11]. In contrast, in our study,
patients with a PDAC in the body were less likely to undergo
resection and patients with a PDAC in the tail are more likely
to undergo resection than patients with a PDAC in the head.
Because PDAC locations in the body are in close relation to
the celiac trunk and major vascular structures (e.g., superior
mesenteric artery, portomesenteric vein), these tumors are
more often considered unresectable. In contrast, a non-meta-
stasized PDAC in the tail with ingrowth in nearby, less vital,
structures (e.g., stomach, spleen, adrenal gland) could more
often undergo resection than a PDAC in the head. In some
patients with PDAC in the head, malignant biliary obstruction
and complications after preoperative biliary drainage, lead to
delay or even omission of surgery [12,13]. As this is not the
case for patients with a PDAC in the tail, this could also par-
tially explain the higher likelihood of resection for tail ver-
sus head.
Patients with PDAC in the body who did not undergo
resection and had no distant metastases were more often
treated with chemotherapy than patients with a location in
the head, which could indicate the primary effort to pre-
operatively reduce these tumors that are more challenging
to resect. This is in line with the higher proportion of
patients with a resected PDAC in the body receiving pre-
operative chemotherapy compared with head or tail. In the
Netherlands, neoadjuvant chemo(radio)therapy was mostly
used in the context of the PREOPANC trial [14] since 2013
for (borderline) resectable PDAC and in the PELICAN trial
(NTR5517) for irresectable PDAC since 2014.
Although palliative chemotherapy is advised in the Dutch
guideline for pancreatic cancer [15], the proportion of
patients with metastases receiving chemotherapy was low in
this study (22–30%). Previously reported rates of palliative
chemotherapy are inconsistent and range from 17% to 54%
[16–20]. If patients are fit, palliative chemotherapy should be
considered as our data in accordance with previous literature
show this can improve survival significantly [21,22].
Overall, the initiation rate of the adjuvant chemotherapy
was low during our study period (48–51%). While this treat-
ment strategy is widely accepted as standard of care, low ini-
tiations rates have also been described in the literature,
ranging from 51% to 68% in various studies [23–26]. This
finding may be attributed to several factors. First, in the
Netherlands, adjuvant chemotherapy rates ranged from 26%
to 74% between 19 pancreatic surgery centers [27]. We
expect this difference to be even larger in non-expert/referral
centers. Perhaps clinicians interpret the guideline differently
and therefore advice on adjuvant treatment may differ. Many
patients receive adjuvant chemotherapy in smaller referral
centers closer to their home. It was previously shown that
high center volume for metastatic pancreatic cancer was
associated with more receipt of palliative chemotherapy [16],
and this association could also exist for adjuvant treatment.
Second, pancreatic surgery has a high complication rate. It is
known that a substantial proportion of patients recover too
late for the start of adjuvant therapy. Third, patients may
choose to not undergo treatment with chemotherapy as
they may believe that it will decrease quality of life.
Survival differences between the different tumor locations
varied per disease stage. In our study, patients without meta-
stases had similar overall survival for the three locations. This
is in contrast with the literature, as better survival is
described for head, body and tail PDAC of local/regional dis-
ease stage in various studies [7,8]. In our study, patients with
metastases from head PDAC showed significantly better
overall survival than patients with body or tail PDAC, while
previous studies found this for metastasized head as well as
metastasized tail PDAC [7,8]. We found a 5-year overall sur-
vival after pancreatic resection of 20% for tail, 14% for head,
yet 7% for body. This is in line with better 3-year relative sur-
vival for body/tail cancers as described previously (20%
body/tail versus 9% head) [7]. It is unclear from that study
whether patients with overlapping locations were included
and whether pathological or clinical stage was used for the
selection of patients [7]. Besides, both studies included ear-
lier time periods in which other TNM editions were used
[7,8]. A clear explanation for the lower 5-year overall survival
for PDAC in the body was not found. Resection margin and
chemotherapy rates were similar to the other tumor loca-
tions, and the proportion of patients without positive lymph
nodes was even significantly higher than in patients with a
PDAC in the head (41% versus 29%, p< .001). Potentially,
patients with a PDAC in the body more often have vascular
involvement due to the nearby celiac trunk, as compared to
other tumor locations, which may lead to worse long-term
outcomes. Considering the outcome variations between
body and tail, the two locations should be assessed separ-
ately in future studies.
It is known that PDAC in the body or tail are often diag-
nosed later due to the lack of specific clinical symptoms,
which leads to detection bias and possibly explains survival
differences according to the tumor location. On the other
hand, Dreyer et al. recently showed that PDAC in the body
and tail may have more aggressive tumor biology compared
to PDAC in the head which may explain worse clinical out-
comes [10]. Within the group with distant metastases, both a
delayed diagnosis and aggressive tumor biology could con-
tribute to the survival difference.
There are several limitations to this study. Firstly, in the
Netherlands Cancer Registry, no comorbidity, postoperative
morbidity data and cause of death are available. In addition,
type of chemotherapy was only registered since 2015 and
could therefore not be analyzed in this study. Secondly, a
recent study suggested that the Netherlands Cancer Registry
underestimates pancreatic cancer incidence of elderly
patients, leading to a small overestimation of survival in this
study [28]. Thirdly, patients with registered tumor location
‘other’ were excluded (14%). In this group, tumor locations
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were partly overlapping (e.g., head/body or body/tail) or ‘not
otherwise specified’ and could therefore not be assigned to
the groups of this study. It is possible that some of the over-
lapping tumors are larger than tumors confined to either
head, body or tail, possibly with worse outcomes. As a result,
survival in this study could be slightly overestimated.
However, the strength of these Netherlands Cancer
Registry data is that it is population based. A large nation-
wide cohort of patients with PDAC in the Netherlands repre-
sents daily clinical practice.
In conclusion, PDAC locations in the pancreatic body or
tail are larger, more often metastasized and less often resect-
able than PDAC in the pancreatic head. Only in patients with
metastatic disease, overall survival of patients with a PDAC in
the body or tail was significantly worse than of patients with
a PDAC in the head.
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